Adia Nutrition sells Biolete coffee subsidiary to focus on healthcare

Adia Nutrition Inc. (OTCQB:ADIA) has divested its Biolete coffee subsidiary to Cement Factory LLC, retaining an 18% ownership stake, to strategically concentrate on its core healthcare business, particularly expanding stem cell sales and regenerative therapies. This move, which follows a 530% year-to-date stock gain for ADIA, will fund medical expansion, including new clinics and the recent introduction of glutathione IV therapies, underscoring the company's pivot towards high-growth medical treatment opportunities.

Analysis

AMD shares surge after AI chip deal with OpenAI WINTER PARK, Florida - Adia Nutrition Inc. (OTCQB:ADIA) announced Monday it has sold its Biolete coffee subsidiary to Cement Factory LLC while retaining an 18% ownership stake in the purchasing company. The stock, currently trading at $0.04, has shown remarkable momentum with a 530% gain year-to-date, according to InvestingPro data. The transaction transfers full operational control of Biolete, which specializes in organic protein and mushroom-infused coffee products, to Cement Factory LLC, a consumer products firm led by Jeff Sciullo and AJ Sims. Adia had acquired Biolete in July 2024. The divestiture allows Adia to concentrate resources on its core healthcare business, particularly expanding stem cell sales, treatments, and clinic-based therapies. "This divestiture sharpens our focus on delivering transformative medical treatments and regenerative therapies, areas where we see unparalleled growth potential," said Larry Powalisz, CEO of Adia Nutrition Inc., according to the company’s press release. Adia plans to use proceeds from the sale to fuel its medical expansion, including the development of additional Adia Med clinics and research for new therapies. The company reports it has already tripled its sales force in 2025 with dedicated regional teams to drive adoption of its regenerative products. Earlier this year, Adia opened its first satellite clinic to expand access to regenerative treatments. The company also secured a court-ordered cancellation of over 25 million improperly issued shares. Biolete’s new owners expressed optimism about the coffee brand’s future. "We’re thrilled to acquire Biolete and build on its reputation for innovative, health-focused beverages," said Sciullo in the announcement. The company did not disclose the financial terms of the transaction. The stock maintains moderate trading activity with a three-month average daily volume of 110,000 shares, while delivering a 350% return over the past year. Investors seeking deeper insights into ADIA’s valuation and growth metrics can access additional analysis through InvestingPro. In other recent news, Adia Nutrition, Inc. announced the expansion of its regenerative medicine portfolio through its subsidiary, Adia Med. The company has introduced glutathione IV therapies into select treatment protocols at its clinics. This addition is designed to complement existing treatments, which include stem cell and exosome therapies for orthopedic conditions, pain management, and wound repair. Alongside the intravenous treatments, Adia Labs has launched a transdermal glutathione spray. These developments are part of Adia Nutrition’s ongoing efforts to enhance its offerings in cellular health and detoxification. Glutathione, a naturally occurring tripeptide, is emphasized for its role in supporting cellular health. The introduction of these therapies marks a strategic move to broaden the company’s medical treatment capabilities. These recent developments highlight Adia Nutrition’s commitment to advancing its medical services. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in ADIA right now? First, check if it's included in one of this month's AI-powered stock strategies for ProPicks AI. Investing.com created these strategies to identify the most exciting trading opportunities currently in the market. The stocks that made the cut could produce monster returns in the coming years, like ViaSat and Sapiens, both up over 60%+ each in Q2 of 2025 alone. Is ADIA one of them? Adia Nutrition Inc. (OTCQB:ADIA) is executing a significant strategic pivot by divesting its Biolete coffee subsidiary to sharpen its focus on the core regenerative medicine business. This M&A activity, where Adia retains an 18% stake in the divested entity, is designed to channel resources and proceeds into its high-growth healthcare operations, including stem cell therapies and clinic expansion. This strategic shift is supported by recent operational execution, such as tripling its sales force in 2025, opening a satellite clinic, and launching new glutathione-based treatments. The move follows a period of extraordinary stock performance, with a 530% year-to-date gain, although the stock remains a micro-cap security trading at $0.04 with a moderate average daily volume of 110,000 shares. A recent court-ordered cancellation of over 25 million improperly issued shares signals a positive step in cleaning up the company's capital structure, potentially reducing overhang for existing shareholders. However, the non-disclosure of the financial terms for the Biolete sale introduces uncertainty regarding the immediate capital injection available for the company's stated expansion plans.

Key Decisions for Investors

• Investors should view ADIA as a high-risk, high-reward pure-play on the regenerative medicine sector, as the recent divestiture clarifies its strategic focus and provides potential funding for growth initiatives.
• Caution is warranted due to the stock's significant 530% year-to-date appreciation, its OTCQB listing, and its moderate trading volume, all of which point to heightened volatility and liquidity risk.
• Monitor future announcements for the deployment of proceeds from the sale and track revenue growth from the expanded sales force and new clinics, as these will be key indicators of whether the new strategy is successfully gaining traction.